Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220249649IMMUNOGEN
US 11.08.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 17622468 Applicant Ecole Polytechnique Federale De Lausanne Inventor Bruno Correia

Polypeptides useful in the preparation of vaccine compositions against RSV are provided. Also disclosed are methods of enhancing subdominant antibody responses in a subject.

2.20220249703ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN SELECTED NEURONAL CELL POPULATIONS
US 11.08.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17431079 Applicant Allen Institute Inventor Jonathan Ting

Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic neurons generally; and/or GABAergic neuron cell types such as lysosomal associated membrane protein 5 (Lamp5) neurons; vasoactive intestinal polypeptide-expressing (Vip) neurons; somatostatin (Sst) neurons; and/or parvalbumin (Pvalb) neuron cell types. Certain artificial expression constructs additionally drive selective gene expression in Layer 4 and/or layer 5 intratelencephalic (IT) neurons, deep cerebellar nuclear neurons or cerebellar Purkinje cells.

3.WO/2022/169344NEWCASTLE DISEASE VIRUS WITH IMPROVED HEAT RESISTANCE, AND NEWCASTLE DISEASE VIRUS VACCINE COMPRISING SAME
WO 11.08.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/KR2022/001899 Applicant BIOPOA, INC. Inventor CHO, Sun Hee
The present specification provides: a Newcastle disease virus with improved heat resistance; a Newcastle disease vaccine comprising the virus; a polypeptide comprising an L protein in the virus; a polynucleotide encoding same; and a recombinant vector comprising the polynucleotide.
4.WO/2022/166954RNA ADENO-ASSOCIATED VIRUS (RAAV) VECTOR AND USES THEREOF
WO 11.08.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/CN2022/075366 Applicant HUIGENE THERAPEUTICS CO., LTD. Inventor SHI, Linyu
Provided is an RNA sequence comprising an RNA sequence of interest and an RNA-packaging signal. Also provided is a recombinant DNA virus viral particle comprising the RNA sequence comprising an RNA sequence of interest and an RNA-packaging signal packaged within the protein shell of a DNA virus.
5.20220249651UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION
US 11.08.2022
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No 17589484 Applicant AEGLE BIOTECH Inventor Beverly W. Lubit

The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (TH) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene under the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.

6.20220251574CELL CAPABLE OF ACTIVATING IMMUNE SYSTEM, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL
US 11.08.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No 17618699 Applicant RIKEN Inventor Shinichiro FUJII

The present invention provides a cell activating the immune system and a pharmaceutical composition containing the cell. According to the present invention, there is provided a mammalian cell having at least one protein selected from the group consisting of E6 protein and E7 protein for early genes of human papillomavirus and a fusion protein of E6 protein and E7 protein, and CD1d protein, wherein the mammalian cell is pulsed with a CD1d ligand. According to the present invention, there are also provided a fusion protein having E7 protein, E6 protein and E7 protein in this order, a nucleic acid encoding the protein and a gene expression vector therefor.

7.WO/2022/170195HYBRID AAV-ANELLOVECTORS
WO 11.08.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2022/015499 Applicant FLAGSHIP PIONEERING INNOVATIONS V, INC. Inventor DELAGRAVE, Simon
This invention relates generally to compositions for making and administering anellovectors and uses thereof.
8.WO/2022/170030METHOD TO REDUCE INFECTIVITY OF SAMPLES WITH RETENTION OF DIAGNOSTIC SIGNAL
WO 11.08.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/US2022/015203 Applicant QUIDEL CORPORATION Inventor STASSINOPOULOS, Adonis
Methods, assays and devices for detecting the presence or absence of an inactivated form of an infectious pathogen in a biological sample are provided. The methods, assays and devices provide biological samples, suspected of containing infectious pathogens that are less infective so that they can be handled and tested with a reduced risk of infection. However, samples handled in accordance with the present methods maintain features that allow detection of the pathogen in the less infective sample.
9.WO/2022/166026CRE RECOMBINASE INDUCTION-BASED LARGE-SCALE LENTIVIRAL GENE DRUG PREPARATION SYSTEM, AND METHOD
WO 11.08.2022
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/CN2021/093905 Applicant GENMEDICN BIOPHARMA INC. Inventor DONG, Wenji
A Cre recombinase induction-based large-scale lentiviral gene drug preparation system, which comprises: a suspended 293 stable cell line and a virus that expresses the Cre gene; a lentivirus packaging protein expression sequence and a target gene sequence are integrated on the genome of the suspended 293 stable cell line; a LoxP-Stop-LoxP sequence is inserted between the lentivirus packaging protein expression sequence and a promoter driving same to be expressed; the LoxP-Stop-LoxP sequence contains two LoxP sites of a same direction and a Stop sequence connected between the two LoxP sites; the virus that expresses the Cre gene is a virus able to infect a suspended 293 cell and is able to express a Cre protein; the virus that expresses the Cre gene is used for infecting the suspended 293 stable cell line, and activating the lentivirus packaging protein expression sequence to perform expression, so as to package and produce a lentivirus.
10.20220249647COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS
US 11.08.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 17596401 Applicant Janssen Sciences Ireland Unlimited Company Inventor Helen HORTON

Therapeutic combinations of hepatitis B virus (HBV) vaccines and capsid assembly modulators are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described.